Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. Harousseau JL, et al. Among authors: masszi t. Blood. 2009 Aug 6;114(6):1166-73. doi: 10.1182/blood-2009-01-198093. Epub 2009 May 21. Blood. 2009. PMID: 19470696 Free article. Clinical Trial.
[How did the survival of acute myeloid leukemia change over the last ten years in our unit?].
Gaál L, Ruff E, Wiedemann Á, Svorenj S, Szita VR, Tóth AD, Masszi A, Horváth L, Szombath G, Nagy Z, Várkonyi J, Benedek S, Farkas P, Bödör C, Masszi T, Varga G. Gaál L, et al. Among authors: masszi t. Orv Hetil. 2023 Nov 12;164(45):1787-1794. doi: 10.1556/650.2023.32901. Print 2023 Nov 12. Orv Hetil. 2023. PMID: 37952177 Hungarian.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
Pour L, Micheva I, Usenko G, Mikala G, Masszi T, Simeonova K, Thuresson M, Huledal G, Norin S, Bakker NA, Minarik J. Pour L, et al. Among authors: masszi t. Clin Lymphoma Myeloma Leuk. 2024 Feb 23:S2152-2650(24)00091-0. doi: 10.1016/j.clml.2024.02.012. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38490927 Free article.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Schjesvold FH, et al. Among authors: masszi t. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.284635. Online ahead of print. Haematologica. 2024. PMID: 38426292 Free article.
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
László T, Kotmayer L, Fésüs V, Hegyi L, Gróf S, Nagy Á, Kajtár B, Balogh A, Weisinger J, Masszi T, Nagy Z, Farkas P, Demeter J, Istenes I, Szász R, Gergely L, Sulák A, Borbényi Z, Lévai D, Schneider T, Pettendi P, Bodai E, Szerafin L, Rejtő L, Bátai Á, Dömötör MÁ, Sánta H, Plander M, Szendrei T, Hamed A, Lázár Z, Pauker Z, Radványi G, Kiss A, Körösmezey G, Jakucs J, Dombi PJ, Simon Z, Klucsik Z, Gurzó M, Tiboly M, Vidra T, Ilonczai P, Bors A, Andrikovics H, Egyed M, Székely T, Masszi A, Alpár D, Matolcsy A, Bödör C. László T, et al. Among authors: masszi t. J Pathol Clin Res. 2024 Jan;10(1):e351. doi: 10.1002/cjp2.351. Epub 2023 Nov 21. J Pathol Clin Res. 2024. PMID: 37987115 Free PMC article.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Dimopoulos MA, et al. Among authors: masszi t. Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0. Lancet Haematol. 2023. PMID: 37793771 Clinical Trial.
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Manzoor BS, Busman T, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: masszi t. Leuk Lymphoma. 2023 Aug 25:1-4. doi: 10.1080/10428194.2023.2247511. Online ahead of print. Leuk Lymphoma. 2023. PMID: 37626019 No abstract available.
Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á, Szita VR, Horváth R, Szederjesi A, Sebő A, Tóth AD, Masszi T, Varga G. Wiedemann Á, et al. Among authors: masszi t. Pathol Oncol Res. 2023 Apr 28;29:1611171. doi: 10.3389/pore.2023.1611171. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37188125 Free PMC article.
198 results